Drug Database
PG

PG-201 (Layla / PG201)

✓ Approved

PMG Pharm · 治疗药物

什么是 PG-201?

PG-201 是一种治疗药物,由PMG Pharm研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Layla, PG201
公司PMG Pharm
给药途径Oral (PO)
状态Approved

治疗适应症

PG-201 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Musculoskeletal and connective tissue disordersOsteoarthritis✓ Approved
Musculoskeletal and connective tissue disordersRheumatoid arthritisPhase III

相关研究文献

PubMedJournal of cosmetic dermatology2026-11-18

Methodological Considerations in the Evaluation of RLX-201 for Skin Health.

Aiman Ume U, Salar Muhammad M, Umar Komal K

PMID 43047231
阅读全文 →
PubMedJournal of cosmetic dermatology2026-11-18

A Novel TORC1 Inhibitor, RLX-201, Improves Skin Health, Biomechanics, and Extracellular Matrix Integrity in a Double-Blind Clinical Study.

Draelos Zoe D ZD, Mehta Rahul C RC, Jha Manisha M, Day Doris D et al.

Skin aging is characterized by decline in structural integrity, extracellular matrix (ECM) organization, and biomechanical function. Emerging concepts in skin longevity emphasize preservation of tissue resilience through modulation of aging pathways, including mechanistic target of rapamycin complex 1 (TORC1), a central regulator of the 12 currently accepted hallmarks of aging. Evaluate the effect of topical formulations containing RLX-201 on clinical photoaging, skin biomechanics, and molecular biomarkers. In this 12-week, randomized, double-blind, vehicle-controlled study, female subjects with moderate-to-severe facial photoaging applied RLX-201 formulation or vehicle twice daily. Clinical assessments were performed at baseline and Weeks 2, 4, 8, and 12 by an investigator. Skin viscoelastic properties were quantified using elastometry. Subject self-assessments were collected. Mechanistic evaluation was conducted in 3D full-thickness skin tissue models, assessing phosphorylation of ribosomal protein S6 (pRPS6) as a surrogate marker of mTORC1 activity. Treatment with RLX-201 resulted in significant improvements in clinical parameters of skin firmness, elasticity, sagging, and overall skin quality compared with vehicle (p ≤ 0.05), with onset observed as early as Week 2 and sustained through Week 12. Biomechanical analysis demonstrated significant enhancement in viscoelastic properties. Subject-reported outcomes showed high concordance with investigator assessments, with > 85% of participants reporting improvements in radiance, texture, and hydration. Tissue analysis demonstrated suppression of TORC1 activity, with ~91% reduction in pRPS6 expression. Topical modulation of TORC1 improves clinical, biomechanical, and molecular features of skin aging. These findings support a mechanistic approach to enhancing skin health, in which targeting nutrient-sensing pathways enhances tissue resilience and functional performance, extending beyond conventional cosmetic outcomes.

PMID 43047278
阅读全文 →
PubMedJournal of cosmetic dermatology2026-11-18

Periorbital Fat Loss From Prostaglandin Analogues: Dermatologic and Cosmetic Considerations.

Kaufman Lily L, Khuhro Aliza A, Schwierking Sierra S, Valentic Lilia L et al.

Topical prostaglandin (PG) analogues, originally developed as first-line therapies for glaucoma, are increasingly used in dermatology and cosmetic settings to promote eyelash and eyebrow growth. However, their use has been associated with prostaglandin-associated periorbitopathy (PAP), a constellation of adverse effects including periorbital fat atrophy, deepening of the upper eyelid sulcus, ptosis, and skin hyperpigmentation. These changes can be subtle but carry significant aesthetic and psychosocial consequences, particularly in patients using PG analogues for cosmetic enhancement. This review aims to synthesize current knowledge on the clinical features, pathophysiology, and reversibility of PAP, with an emphasis on implications for dermatologic practice. A narrative review of the literature was conducted using PubMed, focusing on dermatologic, ophthalmologic, and cosmetic reports related to PG analogue use and PAP. Although PAP is well recognized in ophthalmology, dermatology-specific data remain sparse. Many over-the-counter eyelash serums contain PG analogues yet lack accurate labeling and regulatory oversight. Diagnostic delays are common, and dermatologists may overlook serum use as a contributing factor in periorbital changes. As the off-label and consumer-driven use of PG analogues continues to rise, dermatologists must remain vigilant in identifying PAP. Routine history-taking should include inquiry about eyelash and eyebrow serums. Greater regulatory oversight, patient education, and dermatology-focused research are needed to promote safe and informed use.

PMID 43047315
阅读全文 →
PubMedClinical medicine insights. Endocrinology and diabetes2026-11-18

Isolated Adrenocorticotropic Hormone Deficiency Secondary to Pembrolizumab-Induced Hypophysitis: A Case of Life-Threatening Adrenal Crisis in a Patient With Metastatic Melanoma.

Sherzodbek Tashbaev T, o'g'li Mamatov Hurshidbek Mirzakamol MHM, Mutalipov Azizbek A, Eshqobilov Ozodbek O et al.

Immune checkpoint inhibitors, particularly programmed cell death protein 1 (PD-1) inhibitors, can cause endocrine immune-related adverse events, including hypophysitis and secondary adrenal insufficiency. Isolated adrenocorticotropic hormone (ACTH) deficiency is uncommon but may present as a life-threatening adrenal crisis. We report the case of a 65-year-old man with stage IV BRAF wild-type metastatic melanoma receiving pembrolizumab who presented with profound fatigue, nausea, vomiting, weight loss, orthostatic dizziness, and hypotension. Laboratory evaluation revealed severe hyponatremia, mild hyperkalemia, hypoglycemia, and acute kidney injury. Serum cortisol was 2.1 µg/dL with an inappropriately low ACTH concentration of <5 pg/mL. A conventional 250 µg cosyntropin (Synacthen) stimulation test demonstrated an inadequate cortisol response, while other pituitary axes remained preserved. Pituitary magnetic resonance imaging showed mild enlargement and stalk thickening, consistent with hypophysitis. Intravenous hydrocortisone and fluid resuscitation rapidly restored hemodynamic and metabolic stability. At 6 months, ACTH remained <5 pg/mL, with persistent isolated corticotroph deficiency. Pembrolizumab-associated isolated ACTH deficiency should be considered when patients develop unexplained constitutional symptoms, hypotension, hyponatremia, or hypoglycemia. Prompt cortisol and ACTH assessment and glucocorticoid treatment are essential to prevent morbidity and mortality.

PMID 43048149
阅读全文 →
PubMedJCEM case reports2026-11-18

Transient hypoparathyroidism and symptomatic hypocalcemia complicating babesiosis.

Amer Bushra B, Phillips Brian B

Babesiosis, caused by Babesia microti, is a tick-borne intraerythrocytic infection with diverse manifestations, but endocrine complications are rarely reported. We describe a 60-year-old man who presented with fever, chills, and cognitive symptoms and was diagnosed with babesiosis by peripheral smear, serology, and polymerase chain reaction. Despite improvement with atovaquone and azithromycin, he developed confusion, paresthesia, and fatigue, prompting further investigation. Laboratory testing revealed hypocalcemia (total calcium, 6.8 mg/dL [SI: 1.7 mmol/L]; reference range, 8.4-10.4 mg/dL [SI: 2.10-2.60 mmol/L]); ionized calcium, 3.8 mg/dL (SI: 0.95 mmol/L; reference range, 4.7-5.5 mg/dL [SI: 1.17-1.37 mmol/L]), a low parathyroid hormone concentration of 9 pg/mL (SI: 9 ng/L; reference range, 18-88 pg/mL [SI: 1.9-9.3 pmol/L]), and hyperphosphatemia, with phosphate concentration of 5.7 mg/dL (SI: 1.84 mmol/L; reference range, 2.5-4.5 mg/dL [SI: 0.81-1.45 mmol/L]), consistent with hypoparathyroidism, with normal magnesium and vitamin D levels. Other etiologies were excluded. He was treated with intravenous calcium followed by oral calcium and calcitriol, resulting in symptomatic and biochemical improvement. Serial monitoring demonstrated gradual recovery of parathyroid function, allowing discontinuation of calcitriol. At follow-up, calcium, phosphate, and parathyroid hormone normalized, and symptoms resolved. This case describes transient hypoparathyroidism associated with babesiosis, with possible cytokine- or immune-mediated mechanisms.

PMID 43047671
阅读全文 →
PubMedJCEM case reports2026-11-18

Differences of sex development associated with asymmetric overgrowth in a patient with 69,XXY/46,XX mosaicism.

Vaiani Elisa E, Caino Silvia S, Marino Roxana R, Daroqui Manuel M et al.

Individuals with both differences in sex development (DSD) and asymmetric overgrowth are rare. This clinical presentation may be associated with chromosomal mosaicism. Multiple methodologies may be needed to establish the diagnosis. An 11-month-old patient was referred for evaluation of DSD and segmental overgrowth. Clinical examination showed right-sided facial enlargement, predominantly left-sided limb overgrowth, macrodactyly, and hypo- and hyperpigmented skin lesions. Genital examination revealed clitoromegaly, a midline urogenital sinus, and a palpable right gonad. Pelvic ultrasonography demonstrated a left-sided hemiuterus and a left intra-abdominal gonad. Gonadal biopsy revealed a dysgenetic testis on the right and an ovary on the left. Serum estradiol was 27 pg/mL (International System of Units [SI], 99.1 pmol/L) (reference range, 7-28 pg/mL [SI, 25.7-102.7 pmol/L]), consistent with female reference values. Post-human chorionic gonadotropin testosterone was 6.3 ng/mL (SI, 21.8 nmol/L) (reference value, >1 ng/mL [SI >3.4 nmol/L]), indicating functional testicular tissue. Peripheral blood karyotype was 46,XX, whereas a fibroblast culture obtained from skin biopsy demonstrated 69,XXY[6]/46,XX[34] mixoploidy. The SRY gene was absent in peripheral blood lymphocytes but was detected in the dysgenetic testis and skin fibroblasts. This case underscores the importance of tissue-directed cytogenetic analysis in individuals with DSD and asymmetric overgrowth when peripheral blood karyotype is normal.

PMID 43047953
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多PG-201